English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Selecting appropriate first line lung cancer therapy
Share :
AACR 2009
18 - 22 Apr 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
8 Jul 2009
Views:
15804
Rating:
Save
Rate video
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.
Categories:
Lung & pleura
Biology
Targeted molecules
Related Videos
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...
18 Oct 2024
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Dr Marina Garassino - University of Chicago, Chicago, USA
26 Sep 2024
ESMO 2024: Latest in EGFR mutated NSCLC
Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof...
16 Sep 2024
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...
12 Jul 2024
Uncommon genetic aberrations NTRK, RET, NRG
Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA
12 Jul 2024
ASCO 2024: Lung cancer highlights
Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...
26 Jun 2024
ASCO 2024: Lung cancer roundup
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
4 Jun 2024
ASCO 2024: Advances in NSCLC
Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo
3 Jun 2024
Osimertinib success in locally advanced EGFR-mutated NSCLC
Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA
3 Jun 2024
More from
e
cancer